“COVID-19 was an opportunity for the field to prove that mRNA vaccines can be quickly developed and they are safe and work very well not only in animal models but also in humans,” Pardi says.

The Trump administration said it was terminating mRNA vaccine research and shifting focus to other approaches, including a ...

The Centers for Disease Control and Prevention (CDC) vaccine advisory group has long had a work group in place to review the ...

Fortunately, the race for a COVID-19 vaccine has a fast-track contender, the mRNA vaccine, which has been developed in a matter of months. It doesn’t contain the virus at all.

It's stunning, actually. When you think about it, the typical flu vaccine, its efficacy is somewhere between 40 and 60 percent. But there's still a lot of work to do here, obviously.

The company’s vaccine against Covid-19 has been a year in the making, Dr. Gregory Glenn, president of research and development for Novavax, told CNN. The work began even before the world ...

Janssen’s coronavirus vaccine is a recombinant vector vaccine. It uses a genetically engineered version of adenovirus 26, which can cause the common cold, but the gene tinkering has disabled it.

Dr. Nita Patel, Director of Antibody discovery and Vaccine development, lifts a vial with a potential coronavirus, COVID-19, vaccine at Novavax labs in Gaithersburg, Maryland, March 20, 2020, one ...

Janssen’s coronavirus vaccine is a recombinant vector vaccine. It uses a genetically engineered version of adenovirus 26, which can cause the common cold, but the gene tinkering has disabled it.

When Johnson & Johnson tested its vaccine in the U.S., it was 72% effective at preventing COVID-19 infection overall but in other regions it was less effective.

With more than 7.5 million confirmed cases worldwide, the new coronavirus has killed more than 420,000. Creating vaccines to protect humans against this threat is a top priority.